CellarisBio is a drug discovery platform utilizing Micro-tag technology to enable the discovery and optimization of therapeutics targeting difficult drug targets like transcription factors and membrane proteins within cellular environments. The platform focuses on developing small molecules, Protacs, peptides, and antibodies to enhance the efficacy of novel therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Many therapeutic targets, such as transcription factors and membrane proteins, are difficult to study and drug due to their complex folding, localization, and function within the cellular environment. Traditional drug discovery methods often fail to accurately represent the biology of these challenging targets, leading to high failure rates in drug development.
Solution
CellarisBio offers the Micro-Tag™ platform, a cell-based target engagement technology that enables the discovery and optimization of therapeutics for challenging drug targets. The platform utilizes enzyme complementation with a fluorescent readout to analyze drug-target interactions within living cells. By preserving the native cellular environment, Micro-Tag™ provides a more physiologically relevant context for validating and analyzing drug candidates. This approach facilitates the identification of compounds that effectively engage and modulate difficult targets, de-risking and accelerating drug discovery programs. The platform supports various therapeutic modalities, including small molecules, peptides, degraders, and antibodies.
Target Audience
CellarisBio's primary customers are pharmaceutical and biotechnology companies engaged in drug discovery, particularly those focused on challenging or previously undruggable targets.
Features
- Micro-Tag™ technology based on enzyme complementation with a fluorescent readout for high sensitivity and dynamic range
- Real-time monitoring of drug-target engagement using conventional thermal shift assays or real-time step gradient methods
- Compatible with DNA-Encoded Libraries (DELs) for de novo drug discovery within the cellular environment
- Versatile assay design with choice of multiple FRET pairs and substrates for modified readouts
- Amenable to high-throughput screening and automation in 384-well format
- Applicable to a wide range of challenging target families, including transcription factors, enzymes, and membrane proteins
- Services include target validation, analysis of cellular target engagement kinetics and mechanism of action, and DEL screening